Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualificat...( WALTHAM Mass. March 30 /- Interleuk...),Health

WALTHAM, Mass., March 30 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that the NYSE Amex LLC (formerly known as the NYSE Alternext US and the American Stock Exchange) has issued a delisting notification to the Company as it has not accepted the plan as drafted and filed in January detailing how the Company intends to regain compliance with Section 1003(a)(iii) of the Exchange's Company Guide by June 23, 2010. The Company has appealed this determination and requested an oral hearing before a committee of the Exchange, which it expects to be scheduled within the next 45 days. The Company will remain listed on the exchange at least until such appeal has been heard.

"We are eager to present in person to the Listing Qualifications Panel to address their questions on our plan. Written documents may not effectively convey the tremendous opportunities for genetic testing across consumer, drug development and clinical diagnostic channels. Interleukin Genetics is now in a leadership position in this field, as over the past year the Company has focused on putting the necessary resources in place to excel in these markets," said Lewis H. Bender, Chief Executive Officer. "The Company has strengthened its management team, refined its focus, renegotiated restrictive agreements and executed on other core deliverables. The results of these efforts are just now beginning to be realized. We are preparing for a Q2 launch of our own genetic test brands and continue to aggressively push to partner our intellectual property and genetic biomarker expertise with additional biotechnology and pharmaceutical companies. We have some new partnerships in place and the capital resources available to fund our operations through the Exchange's monitoring date of June 23, 2010."

As previously disclosed, on December
'/>"/>